BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
19 Outubro 2020 - 10:00AM
Business Wire
ICON continues as part of BARDA’s exclusive
Medical Countermeasures Clinical Studies Network
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
drug and device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries and
government and public health organisations, has been re-selected by
the Biomedical Advanced Research and Development Authority (BARDA)
to continue being part of its exclusive Medical Countermeasures
Clinical Studies Network (CSN).
BARDA, part of the Office of the Assistant Secretary for
Preparedness and Response within the U.S. Department of Health and
Human Services, is responsible for developing medical
countermeasures to secure the U.S. against chemical, biological,
radiological, and nuclear threats, as well as pandemic influenza
and emerging infectious diseases. The CSN provides BARDA partners
with vital technical and regulatory assistance to develop vaccines,
therapeutics, diagnostics, and medical devices to prevent or treat
the medical consequences of these threats.
ICON continues to be a part of The Clinical Trials Planning and
Execution component of the CSN, responsible for planning and
executing clinical studies to support medical countermeasure
development.
“We are proud to be re-selected for this important work, and to
play our part in developing medical countermeasures to save lives,
and keep people safe,” said Dr James Cummings, President, ICON
Government and Public Health Solutions. “ICON is a world-leader in
drug development, and our teams have worked on vaccines and
therapeutics for every major pandemic in the last 30 years. We look
forward to continuing to make our clinical expertise available to
BARDA partners as part of the Medical Countermeasures Clinical
Studies Network.”
About ICON plc
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently operates from 94 locations in 40 countries and has
approximately 15,250 employees as of September 30, 2020.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005399/en/
ICON Media Contact Gareth Arnold Weber Shandwick
Telephone: (+44) 07944 688281 GArnold@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024